Research:

1. We develop systems biology methodologies to elucidate the tumor and immune cell interactions in therapeutic resistance.

2. Dr. Fertig directs an NCI funded hybrid computational and experimental lab in the systems biology of cancer and therapeutic response. Her wet lab develops time course models of therapeutic resistance and performs single cell technology development. Her computational methods blend mathematical modeling and artificial intelligence to determine the biomarkers and molecular mechanisms of therapeutic resistance from multi-platform genomics data. These techniques have broad applicability beyond her resistance models, including notably to the analysis of clinical biospecimens, developmental biology, and neuroscience.

3. Immunotherapy, Cancer Systems Biology, Computational Biology, Computational Immunology, Precision Medicine, Single Cell Technologies

Publications and Interests: https://jhu.pure.elsevier.com/en/persons/elana-fertig